Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Implication of DNMT3A and TET2 Genes Mutations in Cytogenetically Normal Acute Myeloid Leukemia.

Asian Pacific journal of cancer prevention : APJCP - 1 Dec 2022

Aref Salah, Sallam Nahed, Abd Elaziz Sherin, Salama Osama, Al Ashwah Shaimaa, Ayed Mohamed

Abstract excerpt

BACKGROUND: Refining risk stratification of cytogenetically normal AML (CN-AML) cases is important for decision making and tailoring of therapy. In this context genetic and epigenetic mutations was considered. Among these epigenetic regulators are DNMT3A & TET2 genes. Therefore, the aim of this study was to determine the prevalence of DNMT3A and TET2 genes mutations and their impact on the outcome of adult AML...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cross-Sectional Studies
Share to Dioxygenases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA-Binding Proteins

Share to DNA (Cytosine-5-)-Methyltransferases

Share to DNA Modification Methylases

Share to Leukemia, Myeloid, Acute

Share to Nucleophosmin

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 36580013
DOI: 10.31557/APJCP.2022.23.12.4299
PMCID: PMC9971478

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Implication of DNMT3A and TET2 Genes Mutations in Cytogenetically Normal Acute Myeloid Leukemia.PMID 36580013Read ↗

TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns.Semantic proximity Read ↗

TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.Semantic proximity Read ↗

Acute myeloid leukaemia genomics.Semantic proximity Read ↗

A concise review on the molecular genetics of acute myeloid leukemia.Semantic proximity Read ↗

Mutational profiling of acute myeloid leukemia with normal cytogenetics in Brazilian patients: the value of next-generation sequencing for genomic classification.Semantic proximity Read ↗

Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.Semantic proximity Read ↗

Loss of TET2 with reduced genomic 5-hmC is associated with adverse-risk AML.Semantic proximity Read ↗

TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemiaSemantic proximity Read ↗

The evolving molecular genetic landscape in acute myeloid leukaemia.Semantic proximity Read ↗

The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysisSemantic proximity Read ↗

TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public databaseSemantic proximity Read ↗

Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.